RenalGuard significantly reduces risk of contrast-induced acute kidney injury in high-risk patients undergoing interventional procedures

182
RenalGuard

A new meta-analysis, published in JACC: Cardiovascular Interventions, indicates that RenalGuard (RenalGuard Solutions) significantly reduces the risk of contrast-induced acute kidney injury in high-risk patients undergoing percutaneous coronary intervention (PCI) or transcatheter aortic valve implantation (TAVI). Study authors Alessandro Putzu (Department of Cardiovascular Anesthesia and Intensive Care, Cardiocentro Ticino, Lugano, Switzerland) and others report that lowering the incidence of contrast-induced acute kidney injury could have a strong positive economic impact on healthcare costs.

The report, an independent systematic review and meta-analysis of four previously published randomized controlled clinical trials, found that RenalGuard Therapy was associated with a highly significant reduction of contrast-induced acute kidney injury (7.76% vs. 21.43%; p<0.00001), a significantly lower need for patient dialysis (p=0.02 for the comparison) and a consistent, positive, trend towards lower rates of  mortality post procedure.

Andrew Halpert, president, RenalGuard Solutions, comments: “We are grateful to the authors, whose detailed analysis shows that RenalGuard not only lowers the incidence of contrast-induced acute kidney injury, but also offers a real benefit for patients and health care payers by significantly reducing the need for dialysis. This detailed review adds strongly to the growing body of clinical evidence that RenalGuard can significantly lower healthcare risks arising from the use of medically valuable but potentially toxic contrast agents used today in a variety of diagnostic and interventional coronary procedures. We expect these findings to continue to drive adoption of RenalGuard therapy in Europe and other areas where it currently available, and we look forward to further adding to these findings through our ongoing USA pivotal trial, which we expect to complete around the end of this year.”

The meta-analysis authors noted that lowering the incidence of contrast-induced acute kidney injury, which would also lead to an associated significant reduction in the need for dialysis, could have a strong positive economic impact on health care costs.

 

 

(Visited 16 times, 1 visits today)